No licensed hantavirus vaccine exists worldwide, and the 94.5% market-implied probability of no approval or availability by end-2026 reflects the early development stage of all candidates. Promising mRNA platforms, including single-dose formulations from UTMB that achieved full protection in Syrian hamster models against Andes virus, remain preclinical or advancing toward initial human trials, while Korea University’s Moderna-collaborative project and a UK MVA-based Phase 1 study focus on safety and immunogenicity optimization through 2026. Historical timelines for novel vaccines, absence of Phase 3 efficacy data, strain diversity, and the need for GMP manufacturing plus regulatory review create substantial barriers. An accelerated emergency-use pathway following a large outbreak could narrow the gap, though current surveillance and trial schedules make that outcome improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
6% chance
$130,985 Vol.
$130,985 Vol.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists worldwide, and the 94.5% market-implied probability of no approval or availability by end-2026 reflects the early development stage of all candidates. Promising mRNA platforms, including single-dose formulations from UTMB that achieved full protection in Syrian hamster models against Andes virus, remain preclinical or advancing toward initial human trials, while Korea University’s Moderna-collaborative project and a UK MVA-based Phase 1 study focus on safety and immunogenicity optimization through 2026. Historical timelines for novel vaccines, absence of Phase 3 efficacy data, strain diversity, and the need for GMP manufacturing plus regulatory review create substantial barriers. An accelerated emergency-use pathway following a large outbreak could narrow the gap, though current surveillance and trial schedules make that outcome improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists worldwide, and the 94.5% market-implied probability of no approval or availability by end-2026 reflects the early development stage of all candidates. Promising mRNA platforms, including single-dose formulations from UTMB that achieved full protection in Syrian hamster models against Andes virus, remain preclinical or advancing toward initial human trials, while Korea University’s Moderna-collaborative project and a UK MVA-based Phase 1 study focus on safety and immunogenicity optimization through 2026. Historical timelines for novel vaccines, absence of Phase 3 efficacy data, strain diversity, and the need for GMP manufacturing plus regulatory review create substantial barriers. An accelerated emergency-use pathway following a large outbreak could narrow the gap, though current surveillance and trial schedules make that outcome improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$130,985End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine exists worldwide, and the 94.5% market-implied probability of no approval or availability by end-2026 reflects the early development stage of all candidates. Promising mRNA platforms, including single-dose formulations from UTMB that achieved full protection in Syrian hamster models against Andes virus, remain preclinical or advancing toward initial human trials, while Korea University’s Moderna-collaborative project and a UK MVA-based Phase 1 study focus on safety and immunogenicity optimization through 2026. Historical timelines for novel vaccines, absence of Phase 3 efficacy data, strain diversity, and the need for GMP manufacturing plus regulatory review create substantial barriers. An accelerated emergency-use pathway following a large outbreak could narrow the gap, though current surveillance and trial schedules make that outcome improbable before year-end.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions